Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2015

View Archived Issues

Ebola vaccine based on the 2014 Zaire Guinea epidemic strain: Phase I clinical data

First preclinical data on Boehringer Ingelheim's novel MEK/Aurora kinase inhibitor

Pfizer reflects on achievements of first quarter 2015

EMA grants orphan drug designation to EspeRare's rimeporide for DMD

Braeburn acquires two new schizophrenia therapies

Preclinical findings with ADC BAY-1187982 lead to clinical study

Preliminary phase III results of Civacir to prevent HCV reinfection in liver transplant patients

Theraclone Sciences to screen antibodies from survivors of Ebola virus infection

Singulex and Dutch Technology Foundation launch Biomarker Development Center

Anti-CD73 MAb enhances antitumor activity of anti-PD-1 treatment

Sichuan Haisco Pharmaceutical discloses FXa inhibitors

Acetylon Pharmaceuticals patents HDAC inhibitors

Boehringer Ingelheim reports development of GlyT-1 inhibitors

Merck & Co. describes new Fc-containing polypeptides

Lilly presents novel NAMPT inhibitors

CytoDyn submits full phase III protocol to FDA for PRO-140 in HIV

Cypher Genomics and University of Pennsylvania to research genetic factors in PSP

Retrophin's RE-024 receives U.S. orphan drug designation for PKAN

Tenapanor fails to significantly reduce albuminuria in patients with CKD and type 2 diabetes

NCI launches phase III trial testing strategies for prevention of anal cancer

Primary endpoint met in phase IIb study of clazakizumab for rheumatoid arthritis

Teva reiterates proposal to acquire Mylan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...